Kenneth W Mahaffey

Author PubWeight™ 6.48^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).	Am Heart J	2015	1.57
2	Independent data monitoring committees: preparing a path for the future.	Am Heart J	2014	0.97
3	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.	Am Heart J	2016	0.83
4	Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.	Am Heart J	2014	0.83
5	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).	Am Heart J	2014	0.82
6	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.	Am Heart J	2016	0.78
7	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.	J Am Heart Assoc	2016	0.75
8	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).	Am Heart J	2015	0.75
9	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.	Am Heart J	2016	0.75
10	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.	Am Heart J	2017	0.75